GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » Institutional Ownership

Moleculin Biotech (Moleculin Biotech) Institutional Ownership : 4.88% (As of Apr. 29, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Moleculin Biotech's institutional ownership is 4.88%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Moleculin Biotech's Insider Ownership is 38.93%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Moleculin Biotech's Float Percentage Of Total Shares Outstanding is 96.27%.


Moleculin Biotech Institutional Ownership Historical Data

The historical data trend for Moleculin Biotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Institutional Ownership Chart

Moleculin Biotech Historical Data

The historical data trend for Moleculin Biotech can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 9.09 9.09 7.56 7.56 5.53 5.49 5.47 4.88 4.88 4.88

Moleculin Biotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Moleculin Biotech (Moleculin Biotech) Business Description

Traded in Other Exchanges
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.
Executives
Jonathan P. Foster officer: Exec. Vice President and CFO 2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp director, 10 percent owner, officer: Chairman and Acting CEO 1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco director PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker 10 percent owner, officer: President and COO
Michael D Cannon director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth officer: Chief Financial Officer 2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380

Moleculin Biotech (Moleculin Biotech) Headlines

From GuruFocus

Moleculin Reports First Quarter 2023 Financial Results

By PRNewswire PRNewswire 05-11-2023